Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Altered cholesterol, HDL and LDL metabolism, gene variants of APOA1, APOB, and APOE4, and decreased ApoA1 levels have been implicated in other neurologic disorders.
“Altered cholesterol, HDL and LDL metabolism, gene variants of APOA1, APOB, and APOE4, and decreased ApoA1 levels have been implicated in other neurologic disorders [21–35].”
From Sterol and lipid analyses identifies hypolipidemia and apolipoprotein disorders in autism associated with adaptive functioning deficits (2021) · cites this paper as [28]
Cited by
Sorted by citations
Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69 · see citing works
Merino-Zamorano, C., Fernández-de Retana, S., Montañola, A., Batlle, A., Saint-Pol, J., Mysiorek, C., Gosselet, F., Montaner, J., & Hernández-Guillamon, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150976 · Cited by 63 · see citing works
Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
Ma, C., Li, J., Bao, Z., Ruan, Q., & Yu, Z. (2015) · BioMed Research International · doi:10.1155/2015/481621 · Cited by 46 · see citing works
Tierney, E., Remaley, A. T., Thurm, A., Jager, L. R., Wassif, C. A., Kratz, L. E., Bailey-Wilson, J. E., Bukelis, I., Sarphare, G., Jung, E. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01580-8 · Cited by 26 · see citing works
- Authors
- Kawano, M., Kawakami, M., Otsuka, M., Yashima, H., Yaginuma, T., & Ueki, A.
- Affiliations
- Jichi Medical University (JP)
- Corresponding author
- Kawano, Mikihiko
- Venue
- Clinica Chimica Acta
- Publisher
- Elsevier BV
- Published
- 1995-08
- Volume
- 239
- Issue
- 2
- Pages
- 209-211
- ISSN
- 0009-8981 (ISSN-L)
- OpenAlex
- W1979594847
- Cited by
- 68
- References
- 0
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 4 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 9 · 2014: 6 · 2013: 1 · 2012: 2
- FWCI
- 0.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinica Chimica Acta (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- Alzheimer's disease, apolipoprotein A-I, apolipoprotein A-II, advanced glycation end products, Nε-(carboxyethyl)lysine, post-translational modification, autoantibodies, IgM, biomarkers, disease progression, neurodegeneration
- MeSH terms
- Aged, Alzheimer Disease, Female, Humans, Japan, Lipids, Male, Apolipoprotein A-I, Apolipoprotein A-II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
